Several clinical trials have shown that combination therapy of erlotinib plus VEGF/VEGFR blockade improves the PFS or OS in comparison to erlotinib alone in patients with EGFR-positive NSCLC [24–26]. Here, EGFR is linked to non-small cell lung carcinoma.